Ardsley Advisory Partners’s Pacific Biosciences PACB Stock Holding History

Ardsley Advisory Partners’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-701,500	Closed	-$5.86M	–	166
2023 Q3	$5.86M	Sell	701,500 -204,500	-23%	-$2.34M	1.31%	23
2023 Q2	$12M	Hold	906,000	–	–	2.04%	9
2023 Q1	$10.5M	Buy	906,000 +1,000	+0.1%	+$9.94K	2.3%	11
2022 Q4	$7.4M	Buy	+905,000	New	+$7.8M	1.53%	27
2016 Q4	–	Sell	-15,000	Closed	-$134K	–	165
2016 Q3	$134K	Hold	15,000	–	–	0.02%	146
2016 Q2	$106K	Buy	15,000 +5,000	+50%	+$45.7K	0.02%	145
2016 Q1	$85K	Buy	+10,000	New	+$98.3K	0.01%	137

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Ardsley Advisory Partners's PACB Position: Q4 2023 in Review

Ardsley Advisory Partners sold out of Pacific Biosciences (PACB) in Q4 2023, closing a stake of 701,500 shares — an estimated $5.86M sold.

Ardsley Advisory Partners first reported a position in PACB in Q1 2016 and held it in 7 quarters. The position peaked at $12M in Q2 2023. 274 funds tracked by Wall St. Rank hold PACB as of Q4 2023.

Ardsley Advisory Partners reported no remaining Pacific Biosciences position as of Q4 2023 after selling out during the quarter.
Ardsley Advisory Partners sold 701,500 Pacific Biosciences shares in Q4 2023, an estimated $5.86M.
Ardsley Advisory Partners first reported a position in Pacific Biosciences in Q1 2016 and held it in 7 quarters.
Ardsley Advisory Partners's Pacific Biosciences position peaked at $12M in Q2 2023.
274 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2023.

Based on Ardsley Advisory Partners's 13F filing for Q4 2023, filed 14 Feb 2024.